The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Xie Lan since 2013.
The trader's CIK number is 1555794.
At the time of the last reporting, Xie Lan was the VP Finance, China CFO of Sciclone Pharmaceuticals Inc. (stock ticker symbol SCLN).
Also see all insider trading activities at Sciclone Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | SCLN | 0 | $0 | 12,000 | $130,350 | 20,000 | $0 |
| 2016 | SCLN | 0 | $0 | 32,832 | $340,500 | 32,832 | $151,486 |
| 2015 | SCLN | 0 | $0 | 40,834 | $379,922 | 40,834 | $193,838 |
| 2014 | SCLN | 0 | $0 | 36,468 | $254,036 | 36,468 | $177,234 |
| 2013 | SCLN | 0 | $0 | 0 | $0 | 1,032 | $5,356 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-10-13 | SCLN | Option Ex | 8,000 | .00 | 0 |
| 2017-08-15 | SCLN | Option Ex | 10,000 | .00 | 0 |
| 2017-08-16 | SCLN | Sale | 10,000 | 11.00 | 110,000 |
| 2017-06-12 | SCLN | Option Ex | 1,000 | .00 | 0 |
| 2017-06-12 | SCLN | Sale | 1,000 | 10.75 | 10,750 |
| 2017-03-15 | SCLN | Option Ex | 1,000 | .00 | 0 |
| 2017-03-16 | SCLN | Sale | 1,000 | 9.60 | 9,600 |
| 2016-08-12 | SCLN | Sale | 32,832 | 10.37 | 340,500 |
| 2016-08-12 | SCLN | Option Ex | 32,832 | 4.61 | 151,486 |
| 2015-12-03 | SCLN | Option Ex | 14,166 | 4.75 | 67,246 |
| 2015-12-03 | SCLN | Sale | 14,166 | 9.50 | 134,577 |
| 2015-05-15 | SCLN | Option Ex | 26,668 | 4.75 | 126,592 |
| 2015-05-15 | SCLN | Sale | 26,668 | 9.20 | 245,345 |
| 2014-09-02 | SCLN | Sale | 36,468 | 6.97 | 254,036 |
| 2014-09-02 | SCLN | Option Ex | 36,468 | 4.86 | 177,234 |
| 2013-08-14 | SCLN | Option Ex | 1,032 | 5.19 | 5,356 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Xie Lan (VP Finance, China CFO of Sciclone Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.